San Francisco’s FibroGen has a new name. The biopharmaceutical company announced on Wednesday, January 7 that it is rebranding to Kyntra Bio, and its shares climbed about 5 percent on the news. From the market open on January 8, 2026, the stock trades on Nasdaq under the fresh symbol KYNB, closing the book on the FibroGen identity the company carried through decades of anemia and fibrosis research.
Behind the new letterhead sits a slimmed-down company. Over 2025, FibroGen sold its China business and paid off its senior secured term loan, moves management says stretched its cash runway into 2028. “2025 was a transformational year, highlighted by the sale of FibroGen China, the payoff of our senior secured term loan, and the extension of our cash runway into 2028”, Chief Executive Officer Thane Wettig said, adding that the company now aims at “creating outsized impact for patients and shareholders”.
The renamed firm is pointed at oncology and rare disease. Wettig said Kyntra Bio is “laser-focused” on its mid- and late-stage assets: FG-3246, a first-in-class antibody drug conjugate aimed at the CD46 target and also known as FOR46, now in Phase 2 development for metastatic castration-resistant prostate cancer; FG-3180, a matching PET imaging agent; and roxadustat, a Phase 3-ready drug that just won Orphan Drug Designation from the U.S. Food and Drug Administration for myelodysplastic syndromes. The company has also handed the FDA a pivotal Phase 3 trial protocol for roxadustat in lower-risk MDS anemia among heavily transfused patients.
The calendar ahead is crowded. Topline results from an investigator-sponsored Phase 1b/2 study of FG-3246 paired with enzalutamide in prostate cancer patients, run by UCSF, are due at the ASCO GU meeting in the first quarter of 2026, with interim results from the Phase 2 monotherapy trial expected in the second half of the year. That trial will also test how well FG-3180 predicts which tumors respond, by measuring CD46 expression against reaction to the drug.
Roxadustat already carries approvals in Europe, Japan and a long list of other markets for anemia in chronic kidney disease, on dialysis and off, giving the slimmed-down company an approved product abroad even as it rebuilds at home. Alongside the name change, Kyntra Bio is refreshing its corporate website, and the company noted that its CUSIP number is untouched. For a firm that spent 2025 selling assets and clearing debt, the ticker swap is the visible edge of a bet that three drugs can carry a new name.
Sources
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
- FibroGen rebrands as Kyntra Bio, shares rise · Business Upturn
